Biological Psychiatry
October 15, 2018
Sade M Spencer, Daniela Neuhofer, Vivian C Chioma et al.
Cannabis is the most widely used illicit drug, but knowledge of the neurological consequences of cannabis use is deficient. Two primary components of cannabis are Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD). We established a THC+CBD model of self-administration and reinstated drug seeking to determine if, similar to other addictive drugs, cannabis produces enduring synaptic changes in...
Routledge eBooks
October 10, 2018
Carlene Taylor
1 citation
Clients with attention-deficit/hyperactivity disorder (ADHD) often experience great social difficulties, emotional dysregulation and difficulty succeeding in academic and work settings. ADHD is often present with co-morbid conditions of depression and anxiety. There appears to be reasonable evidence to suggest inclusion of mindfulness practices can be beneficial to the client struggling with...
Drug and Alcohol Review
October 9, 2018
F. Fernández-Calderón, C. Díaz-Batanero, Monica J Barratt et al.
Introduction and Aims: Polysubstance users are a high-risk population for negative health-related consequences. Although some studies have described harm reduction strategies adopted by polysubstance users, studies have not examined their effectiveness in minimising health-related consequences. We aimed to identify dosing-related harm reduction strategies in a sample of polysubstance-using...
The Annual Review of Pharmacology and Toxicology
October 9, 2018
Todd D Gould, Carlos A. Zarate, Scott M. Thompson
132 citations
For decades, symptoms of depression have been treated primarily with medications that directly target the monoaminergic brain systems, which typically take weeks to exert measurable effects and months to exert remission of symptoms. Low, subanesthetic doses of ( R,S)-ketamine (ketamine) result in the rapid improvement of core depressive symptoms, including mood, anhedonia, and suicidal...
Journal of Clinical Psychology
October 8, 2018
Johannes Mander, Paul Blanck, Andreas B. Neubauer et al.
56 citations
OBJECTIVE: There is scarce research on the effects of mindfulness in individual therapy. As many practitioners integrate mindfulness exercises into individual therapy, empirical evidence is of high clinical relevance. METHOD: We investigated the effects of a session-introducing intervention with mindfulness elements (SIIME) in a randomized, controlled design. The effects of SIIME on therapeutic...
October 5, 2018
A. Sikder, F. Yang, R. Schafer et al.
Objectives: Due to psychological and physical strain, family caregivers of patients with Alzheimer’s disease and related dementias are at high risk for depression and stress related disorders. We investigated the feasibility of a mobile application (App) intervention delivering Mentalizing Imagery Therapy (MIT), which incorporates guided imagery and mindfulness, to facilitate self-regulation...
Psychiatric News
October 2, 2018
Jun Yan
After much time and investment, several new classes of antidepressants may soon be available. When ketamine was found to exert a rapid antidepressant effect by researchers at the National Institute of Mental Health (NIMH) more than a decade ago, it sparked hope for a new generation of treatments for depressive disorders. Now, new drug candidates are finally edging toward the finish line....
October 1, 2018
Нина Дмитриевна Сорокина, افسانه توحیدی, Геннадий Вацлавович Селицкий
Here, we review the results of Russian and foreign researches that are directed to evaluating the role of gamma waves of brain bioelectric activity in higher mental functions in humans under normal conditions and in neurological and mental diseases. The dynamics of gamma activity is analyzed in processes of consciousness, attention, memory, visual-motor coordination, cognitive activity, and...
Experimental and Molecular Medicine
October 1, 2018
Yun-Qiang Wan, Jian-Guo Feng, Mao Li et al.
Ketamine has a rapid, obvious, and persistent antidepressant effect, but its underlying molecular mechanisms remain unknown. Recently, microRNAs (miRNAs) have emerged as important modulators of ketamine’s antidepressant effect. We investigated the alteration in miR-29b-3p in the brain of rats subjected to ketamine administration and chronic unpredictable mild stress (CUMS), and a sucrose...
Brain Research Bulletin
October 2018
Mengxin Shen, Dan Lv, Xu Liu et al.
Previous studies have suggested that rapid reductions in depression-like behaviors are observed in response to sub-anesthetic-doses of ketamine, an N-methyl-d-aspartate receptor (NMDAR) antagonist. Neuropeptide VGF (non-acronymic) is a critical effector of depression-like behaviors and is thought to be involved in the antidepressant actions of ketamine that have been demonstrated. However, the...